About F-MAC

Senior European Medical Affairs expertise, founder-led

F-MAC is a specialist European Medical Affairs consultancy 

supporting clinical-stage biotechnology companies developing 

medicines across Europe.

Founder-led by Dr Lee Finlan, F-MAC provides senior involvement from 

strategy through hands-on field execution, with support scaled to the 

needs and stage of each programme.

Lee is a PhD-trained cancer scientist and experienced European Medical 

Affairs leader whose career spans oncology research, clinical development 

and field medical leadership.

His specialist experience includes pancreatic cancer (PDAC), non-small cell lung cancer (NSCLC), metastatic colorectal cancer (mCRC) and acute myeloid leukaemia (AML), with particular depth in precision oncology and RAS/KRAS-targeted drug development.

A flexible model proven in practice

Lee's industry career has included both outsourced and directly employed European Medical Affairs leadership.

He first worked through Amplity in outsourced Field Medical roles and subsequently led European programmes supporting Halozyme and Mirati Therapeutics. In both cases, the outsourced assignment progressed into a direct Senior Director position with the client. Being retained and appointed directly into senior leadership roles from the outsourced model — twice — provides Lee with first-hand experience of how flexible Medical Affairs capability can support a growing 

biotech before permanent European infrastructure is fully established.

It is an operating model F-MAC understands from both sides.

I previously held European Medical Lead and Senior Director roles at Mirati Therapeutics and Halozyme Therapeutics, leading European field medical teams and contributing to global medical strategy. 

Through F-MAC, I have supported clinical-stage precision-oncology companies developing RAS(ON), menin and PRMT5 inhibitors. My work spans Phase I–III development, investigator engagement, clinical trial support and pre-launch preparation.

Through F-MAC I have supported European clinical development and field medical activity for emerging 

precision-oncology companies. This has included a clinical-stage developer of RAS(ON) inhibitors, supporting its wider pipeline across Europe at critical stages ahead of its European build-out, as well as a menin inhibitor programme in oncology and a PRMT5 inhibitor programme. The work involved investigators, KOLs, clinical centres and global cross-functional teams across Europe, connecting scientific strategy with practical field 

execution and supporting trial recruitment.

Start with what you need. Scale when you need it.

F-MAC brings together three capabilities particularly relevant to clinical-stage biotech:

Scientific Depth
PhD-level scientific grounding in the field p53, cancer stem cells and epigenetics combined with extensive 

experience interpreting emerging oncology and clinical data.

European Field Experience
Hands-on engagement with investigators, KOLs and leading clinical centres across European markets.

Senior Medical Affairs Judgement
Pragmatic support informed by experience spanning Field Medical, Clinical Development and European Medical Affairs leadership.

F-MAC is deliberately flexible. Support can range from a defined project or fractional leadership requirement through to Field Medical and broader outsourced European capability.

Research Background

Before moving into industry, Lee built his career in academic cancer research.

His early research at The Christie Hospital, Manchester included receptor and biomarker immunohistochemistry in breast cancer, including ER, PR, EGFR and HER2.  He subsequently completed a British Skin Foundation-funded PhD at the University of Dundee, investigating UV-dependent regulation of the p53 tumour suppressor pathway. The University of Dundee records the three-year studentship and Lee's award of the PhD for this research. His work during this period contributed to peer-reviewed research on p53 signalling, 

phosphorylation and cancer biology.

Lee later became an MRC Career Development Fellow at the MRC Human Genetics Unit in Edinburgh, where his research extended into p53/p63 biology, cancer stem-cell biology and genome organisation. Contemporary publications explicitly identify him as an MRC Career Development Fellow.

This scientific grounding continues to shape F-MAC's approach: understanding the underlying biology, critically interpreting emerging evidence and engaging investigators on the science behind a clinical programme — not simply communicating prepared messages.

Lee's transition into industry was recognised early in his Medical Affairs career, including recognition in the 

Bronze Medal - PharmaTimes MSL of the Year competition in 2014, alongside further recognition during 

subsequent Field Medical roles.

Discuss Your European Medical Affairs Needs

Whether you require a focused project, European Field Medical capability or senior fractional support, F-MAC would be pleased to discuss your programme.

That combination gives F‑MAC a deep understanding of translational science, trial design and regulatory 

context, plus hands‑on experience engaging with healthcare professionals and shaping evidence 

generation and medical strategies in real world and commercial settings. 

Clients work with F‑MAC to benefit from strategic 

scientific insight, clear clinical perspectives and 

pragmatic execution informed by frontline medical 

affairs experience across Europe. 

Start with what you need.  Scale when you need it